LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Guirguis, Amira; Corkery, John; Stair, Jacqueline; Kirton, Stewart; Zloh, Mire; Goodair, Christine; Schifano, Fabrizio; Davidson, Colin (2015)
Publisher: Emerald
Languages: English
Types: Article
Subjects: B200
Purpose\ud – The purpose of this paper is to determine pharmacists’ knowledge of legal highs (novel psychoactive substances (NPS)).\ud \ud Design/methodology/approach\ud – A questionnaire was handed out at two London pharmacist continuing education events in mid-2014. These events update pharmacists about developments of interest/relevance to the profession and to improve their practice. A total of 54 forms were returned; a response rate of 26 percent.\ud \ud Findings\ud – Most pharmacists had poor knowledge of NPS and many considered that NPS were not important to their work, with few having had to advise customers in this area. Despite this, the majority thought that they had insufficient information about NPS. There was a negative correlation between the age of the pharmacist and knowledge of NPS.\ud \ud Research limitations/implications\ud – The sample is a self-selected one drawn from registered pharmacists working in community pharmacies in northwest London, and thus does not include hospital pharmacies. Self-selection means that respondents may only reflect those who are interested in the NPS phenomenon and not the wider pharmacy community. The geographical area covered may not be representative of London as a whole, or indeed other parts of the UK or other EU countries.\ud \ud Practical implications\ud – It is clear that pharmacists do not know much about NPS but would like to know more. This information might improve their practice.\ud \ud Social implications\ud – Pharmacists, easier to see than general practitioners, could be a useful source of information for NPS misusers.\ud \ud Originality/value\ud – There have been no previous attempts to gauge the level of knowledge by pharmacists of legal highs/NPS in the UK or elsewhere to our knowledge.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Schifano F (2015) Novel Psychoactive substances (NPS): clinical and pharmacological issues. Drugs and Alcohol Today 15 (1) 21-27.
    • 2. Papaseit E, Farre M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr. Opin. Psychiatry 27 (4) 243-50.
    • 3. King LA, Nutt DJ. Deaths from “legal highs”: a problem of definitions. The Lancet 2014; 383: 952.
    • 4. EMCDDA. (2011). Responding to new psychoactive substances. Drugs in focus No 22. December. Lisbon: European Monitoring Centre for Drugs & Drug Addiction. Available at: http://www.emcdda.europa.eu/publications/drugs-in-focus/responding-to-newpsychoactive-substances
    • 5. Deluca P, Davey Z, Corazza O, Di Furia, Farre M, Flesland LH, Mannonen M, Majava A, Peltoniemi T, Pasinetti M, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, van der Kreeft P, Iversen E, Schifano F. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuro-Psychopharmacol & Biol Psychiatry 2012; 39: 221-226
    • 6. Corkery J, Claridge H, Loi B, Goodair C, Schifano F. Drug-related deaths in the UK: Annual Report 2013. International Centre for Drug Policy, St George's University of London. Available at: http://www.sgul.ac.uk/research/projects/icdp/our-workprogrammes/pdfs/drd_ar_2013.pdf
    • 7. Hale KM, Murawski MM, Huerta J. Pharmacist roles in combating prescription drug abuse. J Am Pharm Assoc 2009; 49: 589-92.
    • 8. Future Pharmacists, Standards for the initial training of pharmacists. General Pharmaceutical Council (2011). Accessed on 20/04/2015 from http://www.pharmacyregulation.org/sites/default/files/GPhC_Future_Pharmacists.pdf
    • 9. Wragg, K. Substance use and misuse. 2010. The Centre for Pharmacy Postgraduate Education (CPPE), University of Manchester: HMSO. Accessed on 20/04/2015 from https://www.cppe.ac.uk/learningdocuments/pdfs/substanceuse_ol.pdf
    • 11. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28: 491-496.
    • 12. Anand JS, Gleboacka ML, Korolkiewicz RP. Recreational abuse with benzydamine hydrochloride (tantum rosa). Clin Toxicol: 2007; 45: 198-199.
    • 13. Bersani FS, Corazza O, Simonato P, Mylokosta A, Levari E, Lovaste R, Schifano F. Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy. Gen Hosp Psychiatry 2013; 35: 571-573.
    • 14. Corkery JM, Elliot S, Schifano F, Corazzo O, Ghodse AH. 2-DPMP (desoxypipradrol, 2- benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-ylmethanol, diphenylprolinol): A preliminary review. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39: 253-258.
    • 15. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011; 49: 705-719.
    • 19. Soubry, A. & Browne, J. (2013). Drug misuse and dependency. Department of Health, Home Office, part of National Health Service and Public health. Accessed on 20/04/2015 from https://www.gov.uk/government/policies/reducing-drugs-misuse-and-dependence
    • 20. Department of Health. (2012). Nurse and pharmacist independent prescribing changes announced. Accessed on 20/04/2015 from https://www.gov.uk/government/news/nurseand-pharmacist-independent-prescribing-changes-announced
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article